Posts from April 2018.

There are many reasons why Governor Murphy has prioritized legalizing marijuana, but perhaps the most important reason is the social justice aspect. An article posted on yesterday displayed statistics about marijuana arrests in each state that were gathered from 2016 data from the FBI’s Uniform Crime Reporting program. According to the article’s analysis of the FBI data, New Jersey ranked third in the nation in total marijuana arrests, and second in the nation in marijuana arrest rate (arrests per 100,000 people).[1] Census data, however, reveals the New Jersey ...

Alan Silber a member of Pashman Stein Walder Hayden's Cannabis Law Group was extensively quoted in the Asbury Park Press article, "NJ Marijuana Legalization: Lawyers Say Weed is Good for You."

“So, you have a substance which you’re saying is illegal, which is identical to a substance that is made in the human body to keep us healthy,’’ Silber said. “What’s wrong with that picture?’’

He added, “Medical benefits from the use of marijuana not known in 1971, …and impediments to its lawful use as a result of its Schedule 1 classification, are abundant and glaringly ...


Registration For The Twelfth National Clinical Conference On Cannabis Therapeutics

Pashman Stein Walder Hayden Attorneys Alan Silber, CJ Griffin and Ronny Jo Siegal are set to present on in Jersey City on May 10th at The Twelfth National Clinical Conference on Cannabis Therapeutics hosted by Patients Out of Time.

The Pre-Conference Policy Workshop: Medical Cannabis in the States of Confusion is scheduled for Thursday, May 10, immediately prior to the conference. Patients Out of Time will offer a policy seminar featuring experts in law, science, and policies. This ...

De-Scheduling could have significant impact on how marijuana is regulated in New Jersey

Pashman Stein Walder Hayden filed a Brief De-Scheduling Marijuana today in support of the de-scheduling marijuana, and is in direct response to New Jersey’s Division of Consumer Affairs solicitation for public comment on how marijuana is classified under state law and whether any change in its classification status is warranted.

To reevaluate whether the currently accepted uses for medical marijuana warrant a change in its classification as a “Schedule I” drug in New Jersey, a ...

The New Jersey Division of Consumer Affairs is holding two public comment sessions scheduled on April 19th and April 24th which will be part of the process to re-evaluate, particularly in light of recent changes to this State’s policies on medical marijuana, whether marijuana should remain as a Schedule I drug under the New Jersey Controlled Dangerous Substances Act (the “CDSA”), or be re-classified to Schedule IV (or lower). Marijuana is currently a Schedule I controlled substance, which according to the CDSA means that it “(1) has high potential for abuse; and (2) has no ...

Stay Connected

Recent Posts


Jump to Page

By using this site, you agree to our updated Privacy Policy and our Terms of Use